167 related articles for article (PubMed ID: 18922853)
1. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Heaney NB; Pellicano F; Zhang B; Crawford L; Chu S; Kazmi SM; Allan EK; Jorgensen HG; Irvine AE; Bhatia R; Holyoake TL
Blood; 2010 Mar; 115(11):2241-50. PubMed ID: 20068223
[TBL] [Abstract][Full Text] [Related]
3. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
4. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
Savani BN; Mielke S; Adams S; Uribe M; Rezvani K; Yong AS; Zeilah J; Kurlander R; Srinivasan R; Childs R; Hensel N; Barrett AJ
Leukemia; 2007 Oct; 21(10):2145-52. PubMed ID: 17673900
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
Ureshino H; Shindo T; Sano H; Kubota Y; Ando T; Kidoguchi K; Kusaba K; Itamura H; Kojima H; Kusunoki Y; Miyazaki Y; Kojima K; Tanaka H; Saji H; Oshima K; Kimura S
Int J Hematol; 2020 May; 111(5):733-738. PubMed ID: 31873846
[TBL] [Abstract][Full Text] [Related]
6. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.
Holyoake TL; Jiang X; Jorgensen HG; Graham S; Alcorn MJ; Laird C; Eaves AC; Eaves CJ
Blood; 2001 Feb; 97(3):720-8. PubMed ID: 11157490
[TBL] [Abstract][Full Text] [Related]
7. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
9. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
10. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K
Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ
Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.
Nievergall E; Ramshaw HS; Yong AS; Biondo M; Busfield SJ; Vairo G; Lopez AF; Hughes TP; White DL; Hiwase DK
Blood; 2014 Feb; 123(8):1218-28. PubMed ID: 24363400
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Yong AS; Keyvanfar K; Eniafe R; Savani BN; Rezvani K; Sloand EM; Goldman JM; Barrett AJ
Leukemia; 2008 Sep; 22(9):1721-7. PubMed ID: 18548092
[TBL] [Abstract][Full Text] [Related]
15. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
Tanturli M; Giuntoli S; Barbetti V; Rovida E; Dello Sbarba P
PLoS One; 2011 Feb; 6(2):e17008. PubMed ID: 21347297
[TBL] [Abstract][Full Text] [Related]
17. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients.
Zhu XS; Shi W; An GY; Zhang HM; Song YG; Li YB
Chin Med J (Engl); 2011 Aug; 124(16):2423-30. PubMed ID: 21933581
[TBL] [Abstract][Full Text] [Related]
19. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.
Sconocchia G; Lau M; Provenzano M; Rezvani K; Wongsena W; Fujiwara H; Hensel N; Melenhorst J; Li J; Ferrone S; Barrett AJ
Blood; 2005 Nov; 106(10):3666-72. PubMed ID: 16046526
[TBL] [Abstract][Full Text] [Related]
20. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
